Steve Kornblau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5263096/publications.pdf

Version: 2024-02-01

180 papers	9,902 citations	43973 48 h-index	39575 94 g-index
183 all docs	183 docs citations	183 times ranked	13719 citing authors

#	Article	IF	Citations
1	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	13.9	1,161
2	Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Molecular Cancer Therapeutics, 2006, 5, 2512-2521.	1.9	607
3	Melphalan and purine analogâ€“containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood, 2001, 97, 631-637.	0.6	551
4	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	7.7	380
5	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 2014, 26, 428-442.	7.7	292
6	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 864-876.	7.7	265
7	Functional proteomic profiling of AML predicts response and survival. Blood, 2009, 113, 154-164.	0.6	235
8	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	9.4	231
9	Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood, 2006, 108, 2358-2365.	0.6	230
10	Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell, 2018, 34, 499-512.e9.	7.7	209
11	WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia, 2014, 28, 1171-1174.	3.3	208
12	Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood, 2013, 121, 4166-4174.	0.6	184
13	Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood, 2015, 126, 2491-2501.	0.6	180
14	Metabolic gatekeeper function of B-lymphoid transcription factors. Nature, 2017, 542, 479-483.	13.7	175
15	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	0.8	173
16	BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia, 2014, 28, 1657-1665.	3.3	171
17	Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1135-1149.	4.2	140
18	Notch activation inhibits AML growth and survival: a potential therapeutic approach. Journal of Experimental Medicine, 2013, 210, 321-337.	4.2	139

#	Article	IF	Citations
19	Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine. Journal of Clinical Oncology, 1999, 17, 284-284.	0.8	135
20	Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood, 2010, 116, 4251-4261.	0.6	134
21	Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 1865-1874.	3.2	130
22	Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Annals of Hematology, 2012, 91, 1861-1870.	0.8	129
23	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports, 2015, 13, 2715-2727.	2.9	118
24	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	0.6	110
25	hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell, 2015, 28, 486-499.	7.7	110
26	Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood, 2007, 109, 2999-3006.	0.6	107
27	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood, 2016, 128, 1260-1269.	0.6	104
28	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	3.3	99
29	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 2015, 100, 927-934.	1.7	93
30	Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.. Journal of Clinical Oncology, 1997, 15, 1796-1802.	0.8	88
31	p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia, 2017, 31, 1296-1305.	3.3	87
32	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84
33	Variable slope normalization of reverse phase protein arrays. Bioinformatics, 2009, 25, 1384-1389.	1.8	82
34	High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clinical Cancer Research, 1995, 1, 1051-7.	3.2	79
35	Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. Journal of the National Cancer Institute, 2014, 106, djt440.	3.0	75
36	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood, 2019, 134, 59-73.	0.6	75

#	Article	IF	Citations
37	Low expression of PP2A regulatory subunit B55Î± is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia, 2011, 25, 1711-1717.	3.3	71
38	Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 2226-2235.	3.2	71
39	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	5.7	70
40	The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clinical Cancer Research, 1999, 5, 1758-66.	3.2	68
41	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nature Immunology, 2017, 18, 694-704.	7.0	67
42	Disruption of Wnt/Î²-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clinical Cancer Research, 2018, 24, 2417-2429.	3.2	65
43	Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia, 1996, 10, 1563-9.	3.3	60
44	Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy. Clinical Cancer Research, 2010, 16, 3721-3733.	3.2	59
45	Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood, 2011, 118, 5604-5612.	0.6	58
46	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal, 2019, 9, 4.	2.8	57
47	BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clinical Cancer Research, 2000, 6, 1401-9.	3.2	50
48	Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells. PLoS ONE, 2013, 8, e78453.	1.1	48
49	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	5.7	44
50	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications, 2021, 12, 6071.	5.8	44
51	Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots. Cancer Informatics, 2012, 11, CIN.S9055.	0.9	40
52	Disseminated Intravascular Coagulation in Adult Acute Lymphoblastic Leukemia: Frequent Complications with Fibrinogen Levels Less than 100 mg/dl. Leukemia and Lymphoma, 1996, 21, 85-92.	0.6	37
53	Phosphorylation of GSK3Î±/Î² correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clinical, 2015, 4, 59-68.	4.1	37
54	Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2017, 18, 1618.	1.8	37

#	Article	IF	Citations
55	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	3.3	37
56	Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34â€positive compartment. Cancer, 2012, 118, 5283-5292.	2.0	36
57	Progeny Clustering: A Method to Identify Biological Phenotypes. Scientific Reports, 2015, 5, 12894.	1.6	36
58	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood, 2022, 139, 907-921.	0.6	34
59	Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica, 2018, 103, 810-821.	1.7	33
60	The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Science Translational Medicine, 2020, 12, .	5.8	33
61	Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Research, 1994, 54, 242-6.	0.4	33
62	The protein phosphatase 2A regulatory subunit B55Î± is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1969-1977.	1.9	32
63	Targeting nuclear Î²-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia, 2019, 33, 1373-1386.	3.3	32
64	Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFÎºB/IL1Î² signaling network. Oncotarget, 2016, 7, 20054-20067.	0.8	32
65	Transglutaminase 2 expression in acute myeloid leukemia: Association with adhesion molecule expression and leukemic blast motility. Proteomics, 2013, 13, 2216-2224.	1.3	31
66	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget, 2016, 7, 55083-55097.	0.8	31
67	Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia, 1993, 7, 378-83.	3.3	31
68	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	2.0	31
69	Focal Adhesion Kinase as a Potential Target in AML and MDS. Molecular Cancer Therapeutics, 2017, 16, 1133-1144.	1.9	30
70	Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Research, 1992, 52, 4587-90.	0.4	30
71	BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia. Molecular Cancer Therapeutics, 2013, 12, 2940-2949.	1.9	29
72	Loss of TRIM62 Expression Is an Independent Adverse Prognostic Factor in Acute MyeloidÂLeukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 115-127.e15.	0.2	28

#	Article	IF	Citations
73	Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 45-45.	0.6	28
74	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Computational Biology, 2016, 12, e1004890.	1.5	28
75	Characterization of the ETO and AML1â€"ETO proteins involved in the 8;21 translocation in acute myelogenous leukemia. European Journal of Haematology, 1998, 60, 217-225.	1.1	27
76	Preclinical activity of the novel Bâ€cellâ€specific Moloney murine leukemia virus integration site 1 inhibitor PTC â€209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Science, 2015, 106, 1705-1713.	1.7	27
77	A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia. Nature Biomedical Engineering, 2019, 3, 889-901.	11.6	27
78	PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood, 2015, 126, 1585-1594.	0.6	26
79	Use of Reverse Phase Protein Microarrays to Study Protein Expression in Leukemia: Technical and Methodological Lessons Learned. Methods in Molecular Biology, 2011, 785, 141-155.	0.4	26
80	Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia. Oncotarget, 2015, 6, 14970-14981.	0.8	25
81	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature Communications, 2022, 13, 2801.	5.8	25
82	The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. Nature Cell Biology, 2022, 24, 872-884.	4.6	25
83	Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 1207-1218.	0.6	24
84	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98.	2.8	24
85	Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia. Journal of Hematology and Oncology, 2016, 9, 64.	6.9	20
86	Decomposing the Apoptosis Pathway Into Biologically Interpretable Principal Components. Cancer Informatics, 2018, 17, 117693511877108.	0.9	20
87	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer Journal, 2020, 10, 61.	2.8	20
88	Studying The Right Cell In Acute Myelogenous Leukemia: Dynamic Changes Of Apoptosis And Signal Transduction Pathway Protein Expression In Chemotherapy Resistant Ex-Vivo Selected â€œSurvivor Cellsâ€• Cell Cycle, 2006, 5, 2769-2777.	1.3	19
89	Modeling Protein Expression and Protein Signaling Pathways. Journal of the American Statistical Association, 2012, 107, 1372-1384.	1.8	19
90	Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Frontiers in Immunology, 2017, 8, 1975.	2.2	18

#	Article	IF	Citations
91	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget, 2020, 11, 2387-2403.	0.8	18
92	Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia, 1995, 9, 1735-41.	3.3	17
93	Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opinion on Investigational Drugs, 1999, 8, 2027-2057.	1.9	16
94	Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Molecular Cancer Research, 2018, 16, 1275-1286.	1.5	16
95	Role of MSC-derived galectin 3 in the AML microenvironment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 959-969.	1.9	16
96	Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia. Leukemia, 2005, 19, 1550-1557.	3.3	15
97	STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes and Cancer, 2014, 5, 378-392.	0.6	14
98	LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine, 2019, 44, 126-137.	2.7	14
99	Unexpected High Incidence of Severe Toxicities Associated with Alpha Interferon, Low-Dose Cytosine Arabinoside and All-Trans Retinoic Acid in Patients with Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1999, 35, 483-489.	0.6	13
100	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. Expert Review of Proteomics, 2020, 17, 1-10.	1.3	13
101	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway. Blood, 2021, 138, 2383-2395.	0.6	13
102	Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 1994, 84, 256-61.	0.6	13
103	Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clinical Cancer Research, 1998, 4, 1955-63.	3.2	13
104	Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Molecular Cancer Research, 2018, 16, 1263-1274.	1.5	12
105	VEGFC Antibody Therapy Drives Differentiation of AML. Cancer Research, 2018, 78, 5940-5948.	0.4	12
106	Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clinical Epigenetics, 2021, 13, 21.	1.8	12
107	Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Research, 2001, 61, 3355-60.	0.4	12
108	Histone Modification Patterns Using RPPAâ€Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients. Proteomics, 2018, 18, e1700379.	1.3	11

#	Article	IF	Citations
109	Altered Expression of Retinoblastoma (RB) Protein in Acute Myelogenous Leukemia Does not Result from Methylation of the Rb Promotor. Leukemia and Lymphoma, 1999, 35, 283-288.	0.6	10
110	Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Experimental Hematology, 2007, 35, 842-853.	0.2	10
111	Network analysis of reverse phase protein expression data: Characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16). Proteomics, 2012, 12, 2084-2093.	1.3	10
112	Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood, 2021, 137, 1050-1060.	0.6	10
113	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood, 2020, 136, 43-45.	0.6	10
114	Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2004, 104, 2738-2738.	0.6	9
115	Anti-Apoptotic Proteins, HSP90 and Activated STAT3 Contribute to Busulfan Resistance of Myeloid Leukemia Cells.. Blood, 2007, 110, 3472-3472.	0.6	9
116	PKCÎ´ Regulates Translation Initiation through PKR and eIF2Î± in Response to Retinoic Acid in Acute Myeloid Leukemia Cells. Leukemia Research and Treatment, 2012, 2012, 1-17.	2.0	8
117	The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. Journal of Proteomics, 2021, 233, 104046.	1.2	8
118	Cecaâ€“Cyclophosphamide, Etoposide, Carboplatin and Cytosine Arabinosideâ€“A New Salvage Regimen for Relapsed or Refractory Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1998, 28, 371-375.	0.6	7
119	Biological properties of ligand-dependent activation of the MET receptor kinase in acute myeloid leukemia. Leukemia, 2015, 29, 1218-1221.	3.3	7
120	Mycoplasma contamination of leukemic cell lines alters protein expression determined by reverse phase protein arrays. Cytotechnology, 2018, 70, 1529-1535.	0.7	7
121	Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics - Clinical Applications, 2019, 13, 1800133.	0.8	7
122	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia, 2020, 34, 2914-2924.	3.3	7
123	Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Frontiers in Oncology, 2021, 11, 705627.	1.3	7
124	Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia. Oncogene, 2021, 40, 6166-6179.	2.6	7
125	Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget, 2017, 8, 83354-83369.	0.8	7
126	Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Childrenâ€™s Oncology Group study. Haematologica, 2022, , .	1.7	7

#	Article	IF	Citations
127	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 2021, 13, 6263.	1.7	7
128	Harnessing graftâ€versusâ€malignancy: nonâ€myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology, 2000, 111, 18-29.	1.2	6
129	Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. , 2014, 86, 383-396.		6
130	Survivor Cells Predict Which Patients Will Respond to Therapy with VNP40101M and Ara-C.. Blood, 2004, 104, 2027-2027.	0.6	6
131	New Directions in the Biology and Therapy of Chronic Myeloid Leukemia. Leukemia and Lymphoma, 1992, 6, 89-95.	0.6	5
132	Quantitive Expression of Proliferating Cell Nuclear Antigen by Western Blot (PCNAWB) in Peripheral Blasts Correlates with Remission Induciton in Patients with Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1995, 19, 235-241.	0.6	5
133	Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS. , 2013, , n/a-n/a.		5
134	Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. Blood, 2020, 136, 10-11.	0.6	5
135	Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2020, 136, 7-9.	0.6	5
136	Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. Blood, 2008, 112, 759-759.	0.6	5
137	Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist,. Blood, 2011, 118, 3776-3776.	0.6	5
138	Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy. Blood, 2011, 118, 66-66.	0.6	5
139	Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair. Oncotarget, 2019, 10, 4679-4690.	0.8	5
140	High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins.. Blood, 2006, 108, 107-107.	0.6	5
141	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer Journal, 2022, 12, 43.	2.8	5
142	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia, 2022, 36, 712-722.	3.3	4
143	EphrinB1 Activation As a Potential New Treatment Option in AML. Blood, 2011, 118, 5235-5235.	0.6	4
144	Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NFâ€ºB subunit RelA. Proteomics - Clinical Applications, 2021, , 2100072.	0.8	4

#	Article	IF	Citations
145	Growth-Factor Stimulation Reveals Two Mechanisms of Retinoblastoma Gene Inactivation in Human Myelogenous Leukemia Cells. Leukemia and Lymphoma, 1995, 16, 191-198.	0.6	3
146	Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Review of Proteomics, 2018, 15, 613-622.	1.3	3
147	Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).. Blood, 2006, 108, 1966-1966.	0.6	3
148	Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.. Blood, 2009, 114, 2031-2031.	0.6	3
149	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298.	0.6	3
150	TGF-Î²1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion. Blood, 2012, 120, 3543-3543.	0.6	3
151	Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA).. Blood, 2005, 106, 484-484.	0.6	3
152	Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML. Blood, 2020, 136, 7-7.	0.6	3
153	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfanâ€‰Â±â€‰clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	3
154	Necrotizing fungal gingivitis in a patient with acute myelogenous leukemia: Visible yet obscure. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2018, 30, 50-54.	0.2	2
155	BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses. Blood, 2013, 122, 603-603.	0.6	2
156	Simultaneous Activation of Multiple Signal Transduction Pathways Confers Poor Prognosis in Acute Myelogenous Leukemia.. Blood, 2004, 104, 2992-2992.	0.6	2
157	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. Blood, 2020, 136, 18-20.	0.6	2
158	Loss of H3K27 Methylation Identifies Poor Outcome in Adult-Onset Acute Myeloid Leukemia. Blood, 2020, 136, 24-24.	0.6	2
159	Molecular approaches to the diagnosis and treatment of cancer. Stem Cells, 1993, 11, 129-130.	1.4	1
160	P53 Protein Expression Levels Are Prognostic in AML and Predict for Mutational Status.. Blood, 2007, 110, 2397-2397.	0.6	1
161	Highly Phosphorylated FOXO3A Is An Adverse Prognostic Factor in Acute Myeloid Leukemia.. Blood, 2009, 114, 402-402.	0.6	1
162	hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood, 2014, 124, 2382-2382.	0.6	1

#	Article	IF	Citations
163	Prolonged Administration of Arsenic Trioxide (TrisenoxÂ®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.. Blood, 2004, 104, 4731-4731.	0.6	1
164	Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s).. Blood, 2005, 106, 1219-1219.	0.6	1
165	FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.. Blood, 2009, 114, 1588-1588.	0.6	1
166	Genome-Wide Epigenetic Analysis of Cancer Stem Cells (CSCs) In Acute Myeloid Leukemia.. Blood, 2010, 116, 3640-3640.	0.6	1
167	Low Expression of the Novel Tumor Suppressor Trim62 Is An Independent Adverse Prognostic Factor for Survival In Acute Myeloid. Blood, 2011, 118, 563-563.	0.6	1
168	Antibody Screening. Advances in Experimental Medicine and Biology, 2019, 1188, 149-163.	0.8	1
169	Proteoforms in Acute Leukemia: Evaluation of Age- and Disease-Specific Proteoform Patterns. , 0, , .		1
170	Cytokine Profiling of Acute Meylogenous Leukemia and Myelodysplasia.. Blood, 2006, 108, 2355-2355.	0.6	0
171	Clonal Abnormalities in MSC Derived from AML Bone Marrows. Blood, 2008, 112, 2428-2428.	0.6	0
172	The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both Allâ€“Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. Blood, 2009, 114, 4143-4143.	0.6	0
173	Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML. Blood, 2012, 120, 534-534.	0.6	0
174	Phosphorylation Of GSK3Î² Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood, 2013, 122, 2551-2551.	0.6	0
175	The Use of â€œOmicsâ€•to Guide the Selection of Targeted Therapy. , 2015, , 27-43.		0
176	Valosin-Containing Protein (VCP/p97) Is Prognostically Unfavorable in Subtypes of Acute Leukemia, and Negatively Correlates with UPR-Proteins IRE1 and GRP78. Blood, 2021, 138, 3447-3447.	0.6	0
177	Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. Blood, 2020, 136, 29-31.	0.6	0
178	The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness. Blood, 2020, 136, 1-2.	0.6	0
179	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine Â± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2020, 136, 37-38.	0.6	0
180	Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Expert Review of Proteomics, 2021, 18, 1087-1097.	1.3	0